Tacrolimus

From Citizendium
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Tacrolimus is a "macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro."[1] It is a calcineurin inhibitor. Originally used as an antirejection drug in organ transplantation, it has been found useful in other medicial applications.[2]

Approved indications include therapy for Crohn's disease, and, in drug-eluting stents, as a means of preventing reocclusion after blood vessel revascularization. In topical form, it has been approved for atopic dermatitis.

Tacrolimus, and the related pimecrolimus, have also been employed for a number of off-label uses:[3]

References

  1. Anonymous (2024), Tacrolimus (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. American Society of Health-System Pharmacists, "Tacrolimus - Monograph", Medscape Drug Reference
  3. Bruce Jancin (February 2005), "Tacrolimus, Pimecrolimus Eyed for Off-Label Uses", Skin & Allergy News 36 (2): 22, DOI:10.1016/S0037-6337(05)70555-6